(Bloomberg) — Philip Morris International Inc. agreed to buy U.K. asthma drug maker Vectura Group Plc for $1.2 billion, one of the biggest moves yet by a tobacco company toward treating conditions that its cigarettes can help cause. Philip Morris is offering 150 pence in cash for every Vectura share, the companies said in a statement Friday. That’s 11% higher than Thursday’s closing price, and beats an offer from Carlyle Group Inc. that management had agreed to in May. Vectura shares… Source link
Read More »Psychedelic drugmaker MindMed stumbles in Nasdaq debut, CEO says ‘still very early innings’
MindMed’s (MNMD) Nasdaq debut Tuesday made it the second psychedelic drug developer to be listed on a major U.S. stock exchange. UK-based Compass Pathways (CMPS) went public on the Nasdaq in September, while last week Peter Thiel-backed ATAI Life Sciences filed for an IPO. Just a year ago, New York-based MindMed was a penny stock on the over-the-counter market. Shares fell 29% in their first day of trading on the Nasdaq, but that’s after they ran up 65% Friday and 33% Monday on the OTCQB… Source link
Read More »